View Future GrowthPredilife 과거 순이익 실적과거 기준 점검 0/6Predilife 의 수입은 연평균 -12.9%의 비율로 감소해 온 반면, Biotechs 산업은 연평균 17%의 비율로 증가했습니다. 매출은 연평균 42%의 비율로 증가해 왔습니다.핵심 정보-12.90%순이익 성장률-11.36%주당순이익(EPS) 성장률Biotechs 산업 성장률30.80%매출 성장률42.01%자기자본이익률n/a순이익률-521.47%최근 순이익 업데이트30 Jun 2025최근 과거 실적 업데이트Reported Earnings • Oct 12First half 2025 earnings releasedFirst half 2025 results: Revenue: €392.8k (up 149% from 1H 2024). Net loss: €1.89m (loss narrowed 20% from 1H 2024).Reported Earnings • Jun 09Full year 2024 earnings released: €1.13 loss per share (vs €1.14 loss in FY 2023)Full year 2024 results: €1.13 loss per share. Revenue: €498.7k (up 57% from FY 2023). Net loss: €4.26m (loss widened 1.0% from FY 2023). Revenue is forecast to grow 52% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Biotechs industry in France.Reported Earnings • Apr 27Full year 2021 earnings releasedFull year 2021 results: Net loss: €3.41m (loss widened 52% from FY 2020).Reported Earnings • Sep 29Full year 2020 earnings released: €0.64 loss per share (vs €0.71 loss in FY 2019)Full year 2020 results: Net loss: €2.25m (loss widened 7.1% from FY 2019).모든 업데이트 보기Recent updates공시 • May 27Predilife S.A., Annual General Meeting, Jun 30, 2026Predilife S.A., Annual General Meeting, Jun 30, 2026. Location: 1 rue royale bureaux de la colline, saint cloud FranceNew Risk • May 11New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Negative equity (-€15m). Earnings have declined by 13% per year over the past 5 years. Revenue is less than US$1m (€728k revenue, or US$856k). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (€11.3m market cap, or US$13.2m).New Risk • Dec 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of French stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Negative equity (-€15m). Earnings have declined by 13% per year over the past 5 years. Revenue is less than US$1m (€728k revenue, or US$854k). Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Market cap is less than US$100m (€13.0m market cap, or US$15.2m).Reported Earnings • Oct 12First half 2025 earnings releasedFirst half 2025 results: Revenue: €392.8k (up 149% from 1H 2024). Net loss: €1.89m (loss narrowed 20% from 1H 2024).New Risk • Jul 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of French stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Negative equity (-€13m). Earnings have declined by 17% per year over the past 5 years. Revenue is less than US$1m (€493k revenue, or US$577k). Minor Risks Share price has been volatile over the past 3 months (6.7% average weekly change). Market cap is less than US$100m (€12.1m market cap, or US$14.2m).Reported Earnings • Jun 09Full year 2024 earnings released: €1.13 loss per share (vs €1.14 loss in FY 2023)Full year 2024 results: €1.13 loss per share. Revenue: €498.7k (up 57% from FY 2023). Net loss: €4.26m (loss widened 1.0% from FY 2023). Revenue is forecast to grow 52% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Biotechs industry in France.공시 • May 20Predilife S.A., Annual General Meeting, Jun 23, 2025Predilife S.A., Annual General Meeting, Jun 23, 2025. Location: 1 rue royale bureaux de la colline, batiment b 9e etage, saint cloud FranceNew Risk • May 13New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Negative equity (-€3.5m). Earnings have declined by 16% per year over the past 5 years. Revenue is less than US$1m (€301k revenue, or US$334k). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (€14.0m market cap, or US$15.6m).New Risk • Jul 26New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€4.3m free cash flow). Share price has been highly volatile over the past 3 months (62% average weekly change). Negative equity (-€9.1m). Earnings have declined by 13% per year over the past 5 years. Revenue is less than US$1m (€318k revenue, or US$345k). Minor Risks Shareholders have been diluted in the past year (2.0% increase in shares outstanding). Market cap is less than US$100m (€22.7m market cap, or US$24.6m).New Risk • Apr 22New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Negative equity (-€2.7m). Earnings have declined by 15% per year over the past 5 years. Revenue is less than US$1m (€312k revenue, or US$332k). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (€15.2m market cap, or US$16.2m).New Risk • Mar 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of French stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Negative equity (-€2.7m). Earnings have declined by 15% per year over the past 5 years. Revenue is less than US$1m (€312k revenue, or US$340k). Minor Risks Share price has been volatile over the past 3 months (8.1% average weekly change). Market cap is less than US$100m (€16.9m market cap, or US$18.4m).Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Independent Director Ombline de Villèle was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Apr 27Full year 2021 earnings releasedFull year 2021 results: Net loss: €3.41m (loss widened 52% from FY 2020).Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Independent Director Ombline de Villèle was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Sep 29Full year 2020 earnings released: €0.64 loss per share (vs €0.71 loss in FY 2019)Full year 2020 results: Net loss: €2.25m (loss widened 7.1% from FY 2019).Is New 90 Day High Low • Jan 11New 90-day low: €6.85The company is down 4.0% from its price of €7.10 on 13 October 2020. The French market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 25% over the same period.Is New 90 Day High Low • Nov 06New 90-day high: €8.30The company is up 24% from its price of €6.70 on 07 August 2020. The French market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 12% over the same period.Is New 90 Day High Low • Oct 15New 90-day high: €7.80The company is up 20% from its price of €6.50 on 17 July 2020. The French market is down 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 11% over the same period.매출 및 비용 세부 내역Predilife가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이ENXTPA:ALPRE 매출, 비용 및 순이익 (EUR Millions)날짜매출순이익일반관리비연구개발비30 Jun 251-43031 Mar 251-43031 Dec 240-43030 Sep 240-42030 Jun 240-52031 Mar 240-42031 Dec 230-42030 Sep 230-42030 Jun 230-42031 Mar 230-42031 Dec 220-42030 Sep 220-32030 Jun 220-32031 Mar 220-32031 Dec 210-32030 Sep 210-32030 Jun 210-32031 Mar 210-32031 Dec 200-22030 Sep 200-21030 Jun 200-21031 Mar 200-21031 Dec 190-21030 Sep 190-31030 Jun 190-31031 Mar 190-31031 Dec 180-21030 Sep 180-21030 Jun 180-11031 Mar 180-11031 Dec 170-210양질의 수익: ALPRE 은(는) 현재 수익성이 없습니다.이익 마진 증가: ALPRE는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: ALPRE은 수익성이 없으며 지난 5년 동안 손실이 연평균 12.9% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 ALPRE의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: ALPRE은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(7.2%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: ALPRE의 부채가 자산을 초과하여 자본 수익률을 계산하기 어렵습니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/19 22:02종가2026/06/19 00:00수익2025/06/30연간 수익2024/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Predilife S.A.는 1명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Jean-Pierre LozaIn Extenso Financement & Marché
Reported Earnings • Oct 12First half 2025 earnings releasedFirst half 2025 results: Revenue: €392.8k (up 149% from 1H 2024). Net loss: €1.89m (loss narrowed 20% from 1H 2024).
Reported Earnings • Jun 09Full year 2024 earnings released: €1.13 loss per share (vs €1.14 loss in FY 2023)Full year 2024 results: €1.13 loss per share. Revenue: €498.7k (up 57% from FY 2023). Net loss: €4.26m (loss widened 1.0% from FY 2023). Revenue is forecast to grow 52% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Biotechs industry in France.
Reported Earnings • Apr 27Full year 2021 earnings releasedFull year 2021 results: Net loss: €3.41m (loss widened 52% from FY 2020).
Reported Earnings • Sep 29Full year 2020 earnings released: €0.64 loss per share (vs €0.71 loss in FY 2019)Full year 2020 results: Net loss: €2.25m (loss widened 7.1% from FY 2019).
공시 • May 27Predilife S.A., Annual General Meeting, Jun 30, 2026Predilife S.A., Annual General Meeting, Jun 30, 2026. Location: 1 rue royale bureaux de la colline, saint cloud France
New Risk • May 11New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Negative equity (-€15m). Earnings have declined by 13% per year over the past 5 years. Revenue is less than US$1m (€728k revenue, or US$856k). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (€11.3m market cap, or US$13.2m).
New Risk • Dec 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of French stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Negative equity (-€15m). Earnings have declined by 13% per year over the past 5 years. Revenue is less than US$1m (€728k revenue, or US$854k). Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Market cap is less than US$100m (€13.0m market cap, or US$15.2m).
Reported Earnings • Oct 12First half 2025 earnings releasedFirst half 2025 results: Revenue: €392.8k (up 149% from 1H 2024). Net loss: €1.89m (loss narrowed 20% from 1H 2024).
New Risk • Jul 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of French stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Negative equity (-€13m). Earnings have declined by 17% per year over the past 5 years. Revenue is less than US$1m (€493k revenue, or US$577k). Minor Risks Share price has been volatile over the past 3 months (6.7% average weekly change). Market cap is less than US$100m (€12.1m market cap, or US$14.2m).
Reported Earnings • Jun 09Full year 2024 earnings released: €1.13 loss per share (vs €1.14 loss in FY 2023)Full year 2024 results: €1.13 loss per share. Revenue: €498.7k (up 57% from FY 2023). Net loss: €4.26m (loss widened 1.0% from FY 2023). Revenue is forecast to grow 52% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Biotechs industry in France.
공시 • May 20Predilife S.A., Annual General Meeting, Jun 23, 2025Predilife S.A., Annual General Meeting, Jun 23, 2025. Location: 1 rue royale bureaux de la colline, batiment b 9e etage, saint cloud France
New Risk • May 13New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Negative equity (-€3.5m). Earnings have declined by 16% per year over the past 5 years. Revenue is less than US$1m (€301k revenue, or US$334k). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (€14.0m market cap, or US$15.6m).
New Risk • Jul 26New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€4.3m free cash flow). Share price has been highly volatile over the past 3 months (62% average weekly change). Negative equity (-€9.1m). Earnings have declined by 13% per year over the past 5 years. Revenue is less than US$1m (€318k revenue, or US$345k). Minor Risks Shareholders have been diluted in the past year (2.0% increase in shares outstanding). Market cap is less than US$100m (€22.7m market cap, or US$24.6m).
New Risk • Apr 22New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Negative equity (-€2.7m). Earnings have declined by 15% per year over the past 5 years. Revenue is less than US$1m (€312k revenue, or US$332k). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (€15.2m market cap, or US$16.2m).
New Risk • Mar 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of French stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Negative equity (-€2.7m). Earnings have declined by 15% per year over the past 5 years. Revenue is less than US$1m (€312k revenue, or US$340k). Minor Risks Share price has been volatile over the past 3 months (8.1% average weekly change). Market cap is less than US$100m (€16.9m market cap, or US$18.4m).
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Independent Director Ombline de Villèle was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Apr 27Full year 2021 earnings releasedFull year 2021 results: Net loss: €3.41m (loss widened 52% from FY 2020).
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Independent Director Ombline de Villèle was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Sep 29Full year 2020 earnings released: €0.64 loss per share (vs €0.71 loss in FY 2019)Full year 2020 results: Net loss: €2.25m (loss widened 7.1% from FY 2019).
Is New 90 Day High Low • Jan 11New 90-day low: €6.85The company is down 4.0% from its price of €7.10 on 13 October 2020. The French market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 25% over the same period.
Is New 90 Day High Low • Nov 06New 90-day high: €8.30The company is up 24% from its price of €6.70 on 07 August 2020. The French market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 12% over the same period.
Is New 90 Day High Low • Oct 15New 90-day high: €7.80The company is up 20% from its price of €6.50 on 17 July 2020. The French market is down 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 11% over the same period.